India  

Maiden Pharma may lose import-export licence over cough syrup controversy in Gambia

DNA Monday, 10 October 2022
Maiden Pharma may lose import-export licence over cough syrup controversy in GambiaThe suspension of membership implies that Maiden Pharmaceuticals will not be eligible to receive any incentives.
0
shares
ShareTweetSavePostSend
 

You Might Like


Related news from verified sources

Shocked to hear... Maiden Pharma breaks silence on cough syrup deaths in Gambia


newKerala.com

Haryana STOPS cough syrup production by Maiden Pharma linked to 66 child deaths in Gambia

Earlier on Monday, the Indian Pharma company had released a statement over the reports linking its cough syrups to the deaths of 66 children in Gambia.  
Zee News Also reported by •DNA